Clinical Trials Sponsored by Vitreous -Retina- Macula Consultants of New York

Total 13 results

Vitreous -Retina- Macula Consultants of New York

Completed

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)

United States
Vitreous -Retina- Macula Consultants of New York

Unknown

Intense Treatment Regimen With Intravitreal Aflibercept Injection (I-TRAP)

Neovascular Age-Related Macular Degeneration

United States
Vitreous -Retina- Macula Consultants of New York
Regeneron Pharmaceuticals

Withdrawn

Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment

Fibrovascular Pigment Epithelial Detachment

United States
Vitreous -Retina- Macula Consultants of New York
QLT Inc.

Withdrawn

Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself

Age Related Macular Degeneration
Sequenom, Inc.
Vitreous -Retina- Macula Consultants of New York

Completed

Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

Age Related Macular Degeneration | Choroidal Neovascularization | Central Serous Chorioretinopathy

United States
Vitreous -Retina- Macula Consultants of New York
QLT Inc.

Terminated

Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

Macular Degeneration

United States
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Completed

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) (LAST)

Age Related Macular Degeneration

United States
Vitreous -Retina- Macula Consultants of New York
Regeneron Pharmaceuticals

No longer available

Use of Eylea for the Treatment of an Optic Nerve Hemangioma

Retinal Hemangioma

United States
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Completed

Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

Retinal Vein Occlusion

United States
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Choroidal Neovascularization

United States
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (SEIRA)

Age Related Macular Degeneration | CNV | AMD

United States
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Completed

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

Central Serous Chorioretinopathy

United States
Patrick R. Oellers, MD
Ocular Therapeutix, Inc.

Completed

DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

Vitreo-Retinal Surgery

United States

Clinical Trials Sponsored by Vitreous -Retina- Macula Consultants of New York

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations